Aims: Sebaceous gland carcinoma (SGC) is a malignancy associated with the pilosebaceous unit, and occurs at ocular or non-ocular sites. Cyclooxygenases (COXs) are enzymes that are crucial for lipid metabolism. COX-2 is overexpressed in various cancers, and its inhibition by non-steroidal anti-inflammatory drugs is known to reduce the risk of many cancers. Peroxisome proliferator-activated receptor (PPAR)-γ is a transcription factor involved in adipogenesis. PPAR-γ is a potential therapeutic target for the treatment of malignant tumours, including colon carcinoma. The aim of this study was to explore the status of COX-2 and PPAR-γ as prognostic markers in human eyelid SGC.
Methods And Results: The immunohistochemical expression of COX-2 and PPAR-γ was evaluated in 31 SGC cases. Cytoplasmic expression of COX-2 was detected in 80% of the SGC cases, and nuclear expression of PPAR-γ in 87%. There were significant correlations of PPAR-γ expression with well-differentiated SGC [19/21 (90%)] and of COX-2 overexpression with reduced disease-free survival (P = 0.0441, log rank analysis). COX-2 expression [odds ratio (OR) 3.82, 95% confidence interval (CI) 1.02-14.33, P = 0.046] and lymph node metastasis (OR 0.17, 95% CI 0.04-0.65, P = 0.009) emerged as significant risk factors in the univariate analysis. However, COX-2 expression did not emerge as a significant independent prognostic factor in multivariate analysis.
Conclusions: COX-2 is a potential marker for identifying high-risk SGC patients. Expression of PPAR-γ in eyelid SGC cases reflects terminal sebaceous differentiation. Inhibitors of COX-2 signalling and PPAR-γ agonists are both prospective novel therapeutic targets in the management of eyelid SGC patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/his.12932 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Profiling of pathogenic variants in Japanese patients with sarcoglycanopathy.
Orphanet J Rare Dis
January 2025
Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8502, Japan.
Background: Sarcoglycanopathies (SGPs) are limb-girdle muscular dystrophies (LGMDs) that can be classified into four types, LGMDR3, LGMDR4, LGMDR5, and LGMDR6, caused by mutations in the genes, SGCA, SGCB, SGCG, and SGCD, respectively. SGPs are relatively rare in Japan. This study aims to profile the genetic variants that cause SGPs in Japanese patients.
View Article and Find Full Text PDFDiving into hot topics of salivary gland carcinoma management-an EORTC young and early career investigator survey.
Front Oncol
November 2024
Department of Oncology, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland.
Introduction: Recently, the ASCO and ESMO guidelines on salivary gland carcinomas (SGCs) have been released. However, several crucial points lack strong recommendations due to low or intermediate quality of evidence. To better address these "grey zones" in the guidelines, we conducted a survey among the European Organization for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group (HNCG) members on behalf of the EORTC young and early career investigators.
View Article and Find Full Text PDFTargeted Therapy in Salivary Gland Cancer: Prevalence of a Selected Panel of Actionable Molecular Alterations in a German Tertiary Referral Center Patient Cohort.
Mol Diagn Ther
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany.
Article Synopsis
- Salivary gland carcinomas (SGC) are diverse with 24 subtypes, primarily treated through surgery and radiotherapy, but have a low 5-year survival rate of 20% for patients with recurrence or metastasis.
- A study involving 55 SGC patients investigated various druggable molecular alterations using immunohistochemical staining and fluorescence in situ hybridization, finding a 54.4% prevalence of such alterations, with EGFR overexpression being the most common.
- Targeted therapies like trastuzumab deruxtecan and pembrolizumab may offer new treatment options for patients with RM-SGC who cannot undergo salvage surgery.
Postradiotherapy Response Assessment Using 18 F-FDG PET/CT in Salivary Gland Carcinoma-A Multicenter Study.
Clin Nucl Med
February 2025
Medical Oncology.
Article Synopsis
- A multicenter study analyzed the effectiveness of 18F-FDG PET/CT imaging for evaluating the response of salivary gland carcinoma (SGC) patients after radiation therapy (RT), involving 115 patients over a span of 17 years.
- The study found that 70% of patients showed metabolic complete response (CR) on PET/CT; those with metabolic CR had significantly better long-term outcomes compared to those without.
- The imaging technique demonstrated high accuracy and specificity, particularly in cases with higher pre-treatment tumor aggressiveness, aiding in the early detection of viable tumors and guiding further treatment decisions.*
Longitudinal study of seafood and fish oil supplement intake and risk of persistent tinnitus.
Am J Clin Nutr
December 2024
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States; Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.
Background: Persistent tinnitus is common, disabling, and difficult to treat. Diet has been implicated in tinnitus etiology, but studies are inconsistent, and longitudinal data are scarce. Seafood intake is associated with a lower risk of hearing loss, but the longitudinal association with tinnitus is unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!